Berlin Institute for Population and Development

DGAP-News: Aignostics Raises €14m Series A to Advance AI-powered Pathology

Retrieved on: 
Thursday, September 15, 2022
Immunohistochemistry, H&E, Marie Cassidy, Acceleration, Cdx, Companion diagnostic, Machine learning, BIH, Biomarker, Berlin Institute for Population and Development, MIF, Company, Growth, IHC, Cros, VC, Patient, Clinical trial, Investment, CEO, Technology, Wellington Partners, Â, CTO, Solution, Pathology, Metadata, Diagnosis, Pharmacy, Digital health, Research, AI, GCP, Medical device, Medical imaging, Pharmaceutical industry, Fine chemical, Technical University of Berlin

Recognizing that, Aignostics focuses on building leading AI models for the detailed analysis of tissue samples and associated metadata for its blue-chip pharma and biotech clients.

Key Points: 
  • Recognizing that, Aignostics focuses on building leading AI models for the detailed analysis of tissue samples and associated metadata for its blue-chip pharma and biotech clients.
  • Aignostics AI models go well beyond current off-the-shelf solutions and established approaches.
  • Dr. Rainer Strohmenger, Managing Partner at Wellington Partners commented: We are deeply impressed by the Aignostics team and technology.
  • To date, Aignostics has raised close to 20m in funding from leading VC investors and has offices in Berlin, Germany, and Boston, U.S.

Aignostics Raises €14m Series A to Advance AI-powered Pathology

Retrieved on: 
Thursday, September 15, 2022
Immunohistochemistry, H&E, Marie Cassidy, Acceleration, Cdx, Companion diagnostic, Machine learning, BIH, Biomarker, Berlin Institute for Population and Development, MIF, Company, Growth, IHC, Cros, VC, Patient, Clinical trial, Investment, CEO, Technology, Wellington Partners, Â, CTO, Solution, Pathology, Metadata, Diagnosis, Pharmacy, Digital health, Research, GLOBE, AI, GCP, Medical device, Medical imaging, Pharmaceutical industry, Fine chemical, Technical University of Berlin

Recognizing that, Aignostics focuses on building leading AI models for the detailed analysis of tissue samples and associated metadata for its blue-chip pharma and biotech clients.

Key Points: 
  • Recognizing that, Aignostics focuses on building leading AI models for the detailed analysis of tissue samples and associated metadata for its blue-chip pharma and biotech clients.
  • Aignostics AI models go well beyond current off-the-shelf solutions and established approaches.
  • Dr. Rainer Strohmenger, Managing Partner at Wellington Partners commented: We are deeply impressed by the Aignostics team and technology.
  • To date, Aignostics has raised close to 20m in funding from leading VC investors and has offices in Berlin, Germany, and Boston, U.S.

€7.5 Million Granted to Collaborative PROTO Project led by Charité to Study Pluri’s PLX-PAD Cells for Osteoarthritis Treatment

Retrieved on: 
Tuesday, September 6, 2022
Technology, Pain, OA, Swelling, Man, Conditional sentence, Injection, Science, Osteoarthritis, Job, U.S. Securities and Exchange Commission, Method, Anterior cruciate ligament, GLOBE, Leadership, Twitter, Adult, Patient, Inflammation, Berlin Institute for Population and Development, Investor, Knee, Engineering, Regeneration, PLUR, Disability, European, Center, Arthritis, Nasdaq, Woman, Climate change, Industry, Ministry of Education (Malaysia), Trial of the century, Security (finance), Legislation, Disease, Solution, Pressure, LinkedIn, Homeostasis, Quality of life, Star Trek: Phase II, TASE, Private Securities Litigation Reform Act, Israel Innovation Authority, Health, Mortality, Chronic pain, HIV disease progression rates, Regenerative medicine, Phase, Knowledge, Pharmaceutical industry, Plural

The goal of the PROTO project is to utilize Pluris PLX-PAD cells in a Phase I/IIa study for the treatment of mild to moderate knee osteoarthritis (OA).

Key Points: 
  • The goal of the PROTO project is to utilize Pluris PLX-PAD cells in a Phase I/IIa study for the treatment of mild to moderate knee osteoarthritis (OA).
  • Professor Winkler was also the lead PI in the Phase II and Phase III muscle regeneration studies using Pluris PLX-PAD cells.
  • Having evaluated PLX-PAD in other advanced-stage clinical studies, we see clear potential for this cell-based product to treat OA, Professor Winkler said.
  • This award underscores the vast potential of our PLX-PAD cells to treat chronic disease with regenerative medicine, said Yaky Yanay, Pluris CEO and President.

The BioInnovation Institute supports three international start-ups developing pioneering science in the therapeutics and health tech space

Retrieved on: 
Monday, August 22, 2022
Chronic pain, Helmholtz Association, Berlin Institute for Population and Development, Pain, Degenerative disease, Research, Novo Nordisk Foundation, Therapy, Solution, GDPR, EUR, Hospital, Molecular medicine, Acceleration, BII, Association, Drug development, Growth, Sevenless, Patient, Pharmaceutical industry, Film

The three new ventures are strategically aligned with the BII's focus, developing ground-breaking scientific initiatives across the therapeutics and health tech space.

Key Points: 
  • The three new ventures are strategically aligned with the BII's focus, developing ground-breaking scientific initiatives across the therapeutics and health tech space.
  • Spun out from excellent translational research environments across Europe, VEIL.AI, Myopax and Sevenless Therapeutics each hold great potential in the therapeutic and health tech space.
  • It enables better use of GDPR-free data for life science and diagnostics companies, hospitals and health data hubs.
  • The BioInnovation Institute Foundation (BII) is an international commercial foundation with a nonprofit objective supported by the Novo Nordisk Foundation.

The BioInnovation Institute supports three international start-ups developing pioneering science in the therapeutics and health tech space

Retrieved on: 
Monday, August 22, 2022
Chronic pain, Helmholtz Association, Berlin Institute for Population and Development, Pain, Degenerative disease, Research, Novo Nordisk Foundation, Therapy, Solution, GDPR, EUR, Hospital, Molecular medicine, Acceleration, BII, Association, Drug development, Growth, Sevenless, Patient, Pharmaceutical industry, Film

The three new ventures are strategically aligned with the BII's focus, developing ground-breaking scientific initiatives across the therapeutics and health tech space.

Key Points: 
  • The three new ventures are strategically aligned with the BII's focus, developing ground-breaking scientific initiatives across the therapeutics and health tech space.
  • Spun out from excellent translational research environments across Europe, VEIL.AI, Myopax and Sevenless Therapeutics each hold great potential in the therapeutic and health tech space.
  • It enables better use of GDPR-free data for life science and diagnostics companies, hospitals and health data hubs.
  • The BioInnovation Institute Foundation (BII) is an international commercial foundation with a nonprofit objective supported by the Novo Nordisk Foundation.

PixCell Medical Awarded Grant by International Health-Tech Pilot Program

Retrieved on: 
Tuesday, February 22, 2022
Partnership, Microfluidics, Berlin Institute for Population and Development, Israel Innovation Authority, International, CBC, Viscoelasticity, Complete blood count, Machine learning, FDA, National Association Medical Staff Services, Blood, BIH, Quality of life, Technology, AI, IIA, Solution, CEO, Program, Department, Pharmaceutical industry, Medical device

YOKNEAM ILLIT, Israel, Feb. 22, 2022 /PRNewswire/ -- PixCell Medical , innovator of rapid hematology testing solutions at the point-of-care, today announced that it has been awarded a grant by the International Health-Tech Pilot Program .

Key Points: 
  • YOKNEAM ILLIT, Israel, Feb. 22, 2022 /PRNewswire/ -- PixCell Medical , innovator of rapid hematology testing solutions at the point-of-care, today announced that it has been awarded a grant by the International Health-Tech Pilot Program .
  • The program aims to increase the availability of new medical technologies, improving global patient care through international collaboration.
  • PixCell Medical provides healthcare systems with the only 5-part CBC solution that is FDA-cleared for point-of-care use - the HemoScreen.
  • With over 70 companies vying for the grant during the first round of proposals, Pixcell Medical was one of just four Israeli start-ups to receive funding.